Business
What is DiPT? – A Psychedelic Drug That Causes Your Hearing to Trip Balls
Psilocybin in magic mushrooms, LSD, ayahuasca, and DMT are all foundational psychedelic substances that are known to produce hallucinogenic experiences.
Everyone sees different things on these hallucinogenic compounds. More often than not, we also receive ‘messages’ as we visualize. It’s not uncommon to ‘see’ the earth breathing, trees dancing, and the clouds changing colors or moving quickly while on these drugs. The walls could be moving, colors are enhanced, and we can see things even when our eyes are closed. Since these drugs are often used for spiritual or healing purposes, many have reported seeing their ancestors in these sessions.
Everything in the environment looks and feels electric, and deep inside, we feel blissful or at least, heal from any number of psychological issues that we are going through.
But did you know that there is a psychedelic that let you trip through your ears? And it could be just as powerful as the visual hallucinations.
Meet DiPT
Diisopropyltryptamine is a psychedelic drug, and the only one of its kind, that produces aural or audio hallucinations. Currently, DiPT isn’t restricted to any kind of drug scheduling, and it’s quite rare to locate, save for some vendors on the deep web and in certain headshops, though it’s also sold as a research chemical.
DiPT is a less popular and common drug found in the tryptamine class of psychotropic drugs, related to 5-MeO-DiPT (also known as foxy methoxy) and MiPT. In fact, the street name of DiPT foxy methoxy, as some chemists have been able to synthesize DiPT and sell this synthetic tryptamine.
More famous tryptamines include melatonin, serotonin, psilocybin, and the DMT (dimethyltryptamine) that is used to concoct Ayahuasca brews. Tryptamines are known for their ability to induce fantastic sensory changes which can affect the mood of humans. These are widely used recreationally among young people.
It was Alexander Shulgin who conducted the first human trials of DiPT back in 1975. He would then go on to co-author and produce a paper writing about its psychopharmacology potential for humans in 1981. More information on this drug can be found in a book he wrote in 1997, entitled: TiHKAL (Tryptamines I Have Known and Loved). Because of his work and devotion to psychedelics, he was given the nickname ‘godfather of psychedelics’. Based on what we know about DiPT thanks to Shulgin, it seems that DiPT can be viewed as psychedelic mushrooms – but for the ears. It possesses the unique ability to change how we perceive sound. And since many people experience tinnitus during or after consumption of the drug, this may one day play a role in how we understand this condition.
Aside from Shulgin’s work, there is not much else known about this mysterious drug.
However, in a recent article by the Psychedelic Spotlight, psychedelic neuroscience researcher Zeus Tipado provide some more interesting feedback. “Almost all psychedelics have an audio-visual context, but DiPT purely produces audio artefacts. We don’t have an explanation for it,” he tells them.
“We know that DiPT does effect the same part of the brain as other psychedelics – the auditory cortex, and potentially at a deeper level, the thalamus. The thalamus is basically the part of the brain that processes your whole reality. When you take psychedelics, your thalamus is fed information in a kind of chaotic way, which is partly why things can get weird. But in the case of DiPT, it’s purely auditory chaos,” Tipado says.
He goes on to explain that DiPT is capable of producing aural hallucinations even when there is no sound at all. “Even when there’s no augmentation of auditory senses, auditory hallucinations are produced on DiPT. This gives weight to the idea that the whole experience is being processed by the auditory cortex,” Tipado goes on. “Perhaps this bizarre effect is caused by the beyond human enhancement of things we might not ordinarily hear, like electronic frequencies. But I’d say that’s unlikely. However, like we don’t really have an explanation as to why we experience closed eye visuals on other psychedelics. We just don’t know.”
Take with Caution
DiPT is not as well-researched as other psychedelic drugs, so anyone interested in experimenting with it should proceed with caution. It may cause some unwanted side effects, the most common of which is persistent tinnitus, a painful condition which can last during the session or in rare cases, as long as months after.
High doses of DiPT may also cause a lack of balance or coordination. In extremely high doses, it can also result in visual hallucinations.
In the best-case scenario, users have received entheogenic benefits from DiPT. This means that there is a potential for the drug to be used for therapeutic and healing properties. But just like with all other drugs, the set and setting play a very important role in how your trip turns out to be.
Conclusion
While we still know very little about the possible therapeutic value of DiPT, all we can do is wait and see until more research has been conducted. It may have potentially therapeutic uses, and it also may not. Always remember to stay away from street drugs of any kind to avoid unwanted and possibly dangerous side effects.
New Mexico regulators fined a cannabis operator nearly $300,000 and revoked its license after the company allegedly created fake reports in the state’s traceability software.
The New Mexico Cannabis Control Division (CCD) accused marijuana manufacturer and retailer Golden Roots of 11 violations, according to Albuquerque Business First.
Golden Roots operates the The Cannabis Revolution Dispensary.
The majority of the violations are related to the Albuquerque company’s improper use of BioTrack, which has been New Mexico’s track-and-trace vendor since 2015.
The CCD alleges Golden Roots reported marijuana production only two months after it had received its vertically integrated license, according to Albuquerque Business First.
Because cannabis takes longer than two months to be cultivated, the CCD was suspicious of the report.
After inspecting the company’s premises, the CCD alleged Golden Roots reported cultivation, transportation and sales in BioTrack but wasn’t able to provide officers who inspected the site evidence that the operator was cultivating cannabis.
In April, the CCD revoked Golden Roots’ license and issued a $10,000 fine, according to the news outlet.
The company requested a hearing, which the regulator scheduled for Sept. 1.
At the hearing, the CCD testified that the company’s dried-cannabis weights in BioTrack were suspicious because they didn’t seem to accurately reflect how much weight marijuana loses as it dries.
Company employees also poorly accounted for why they were making adjustments in the system of up to 24 pounds of cannabis, making comments such as “bad” or “mistake” in the software, Albuquerque Business First reported.
Golden Roots was fined $298,972.05 – the amount regulators allege the company made selling products that weren’t properly accounted for in BioTrack.
The CCD has been cracking down on cannabis operators accused of selling products procured from out-of-state or not grown legally:
- Regulators alleged in August that Albuquerque dispensary Sawmill Sweet Leaf sold out-of-state products and didn’t have a license for extraction.
- Paradise Exotics Distro lost its license in July after regulators alleged the company sold products made in California.
Golden Roots was the first alleged rulebreaker in New Mexico to be asked to pay a large fine.
Source: https://mjbizdaily.com/new-mexico-cannabis-operator-fined-loses-license-for-alleged-biotrack-fraud/
Four marijuana companies, including a multistate operator, have filed a lawsuit against U.S. Attorney General Merrick Garland in which they allege the federal MJ prohibition under the Controlled Substances Act is no longer constitutional.
According to the complaint, filed Thursday in U.S. District Court in Massachusetts, retailer Canna Provisions, Treevit delivery service CEO Gyasi Sellers, cultivator Wiseacre Farm and MSO Verano Holdings Corp. are all harmed by “the federal government’s unconstitutional ban on cultivating, manufacturing, distributing, or possessing intrastate marijuana.”
Verano is headquartered in Chicago but has operations in Massachusetts; the other three operators are based in Massachusetts.
The lawsuit seeks a ruling that the “Controlled Substances Act is unconstitutional as applied to the intrastate cultivation, manufacture, possession, and distribution of marijuana pursuant to state law.”
The companies want the case to go before the U.S. Supreme Court.
They hired prominent law firm Boies Schiller Flexner to represent them.
The New York-based firm’s principal is David Boies, whose former clients include Microsoft, former presidential candidate Al Gore and Elizabeth Holmes’ disgraced startup Theranos.
Similar challenges to the federal Controlled Substances Act (CSA) have failed.
One such challenge led to a landmark Supreme Court decision in 2005.
In Gonzalez vs. Raich, the highest court in the United States ruled in a 6-3 decision that the commerce clause of the U.S. Constitution gave Congress the power to outlaw marijuana federally, even though state laws allow the cultivation and sale of cannabis.
In the 18 years since that ruling, 23 states and the District of Columbia have legalized adult-use marijuana and the federal government has allowed a multibillion-dollar cannabis industry to thrive.
Since both Congress and the U.S. Department of Justice, currently headed by Garland, have declined to intervene in state-licensed marijuana markets, the key facts that led to the Supreme Court’s 2005 ruling “no longer apply,” Boies said in a statement Thursday.
“The Supreme Court has since made clear that the federal government lacks the authority to regulate purely intrastate commerce,” Boies said.
“Moreover, the facts on which those precedents are based are no longer true.”
Verano President Darren Weiss said in a statement the company is “prepared to bring this case all the way to the Supreme Court in order to align federal law with how Congress has acted for years.”
While the Biden administration’s push to reschedule marijuana would help solve marijuana operators’ federal tax woes, neither rescheduling nor modest Congressional reforms such as the SAFER Banking Act “solve the fundamental issue,” Weiss added.
“The application of the CSA to lawful state-run cannabis business is an unconstitutional overreach on state sovereignty that has led to decades of harm, failed businesses, lost jobs, and unsafe working conditions.”
Alabama regulators are targeting Dec. 1 to award the first batch of medical cannabis business licenses after the agency’s first two attempts were scrapped because of scoring errors and litigation.
The first licenses will be awarded to individual cultivators, delivery providers, processors, dispensaries and state testing labs, according to the Alabama Medical Cannabis Commission (AMCC).
Then, on Dec. 12, the AMCC will award licenses for vertically integrated operations, a designation set primarily for multistate operators.
Licenses are expected to be handed out 28 days after they have been awarded, so MMJ production could begin in early January, according to the Alabama Daily News.
That means MMJ products could be available for patients around early March, an AMCC spokesperson told the media outlet.
Regulators initially awarded 21 business licenses in June, only to void them after applicants alleged inconsistencies with how the applications were scored.
Then, in August, the state awarded 24 different licenses – 19 went to June recipients – only to reverse themselves again and scratch those licenses after spurned applicants filed lawsuits.
A state judge dismissed a lawsuit filed by Chicago-based MSO Verano Holdings Corp., but another lawsuit is pending.
Source: https://mjbizdaily.com/alabama-plans-to-award-medical-cannabis-licenses-dec-1/
New Mexico cannabis operator fined, loses license for alleged BioTrack fraud
Marijuana companies suing US attorney general in federal prohibition challenge
Alabama to make another attempt Dec. 1 to award medical cannabis licenses
Pot Odor Does Not Justify Probable Cause for Vehicle Searches, Minnesota Court Affirms
New Mexico cannabis operator fined, loses license for alleged BioTrack fraud
Alabama to make another attempt Dec. 1 to award medical cannabis licenses
-
Business1 year agoPot Odor Does Not Justify Probable Cause for Vehicle Searches, Minnesota Court Affirms
-
Business1 year agoNew Mexico cannabis operator fined, loses license for alleged BioTrack fraud
-
Business1 year agoAlabama to make another attempt Dec. 1 to award medical cannabis licenses
-
Business1 year agoWashington State Pays Out $9.4 Million in Refunds Relating to Drug Convictions
-
Business1 year agoMarijuana companies suing US attorney general in federal prohibition challenge
-
Business1 year agoLegal Marijuana Handed A Nothing Burger From NY State
-
Business1 year agoCan Cannabis Help Seasonal Depression
-
Blogs1 year agoCannabis Art Is Flourishing On Etsy